Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical trial, multicenter, open, uncontrolled, to evaluate the effectiveness of the combination of sorafenib and bevacizumab in the treatment of patients with advanced and/or metastatic neuroendocrine tumors [ENSAYO CLINICO DE FASE II, MULTICENTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACION DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTASICO]

Next Previous
Trial Profile

Phase II clinical trial, multicenter, open, uncontrolled, to evaluate the effectiveness of the combination of sorafenib and bevacizumab in the treatment of patients with advanced and/or metastatic neuroendocrine tumors [ENSAYO CLINICO DE FASE II, MULTICENTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACION DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTASICO]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms GETNE0801

Most Recent Events

  • 23 Apr 2023 Results pooled analysis from SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT) published in the European Journal of Cancer
  • 24 Aug 2011 New trial record
  • 01 Sep 2009 Status changed from recruiting to completed according to results published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top